Showing 759 news articles about Hepatitis C treatment

Filters Content type: Editors' picks Topic: Hepatitis C treatment

Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Hepatitis C treatment

Australia's rejection of costly new treatment sofosbuvir a 'death sentence for for Hepatitis C sufferers'

Editor's pick
ABC Online
27 October 2014
Hepatitis C treatment

Ireland: Hepatitis C drug to be made available

Editor's pick
The Irish Times
22 October 2014
Hepatitis C treatment

Advocates Criticize Plans to Restrict N.Y. Hepatitis C Drugs

Editor's pick
Poz magazine news
22 October 2014
Hepatitis C treatment

Unique 'pay if you clear' proposal for new hepatitis drug

Editor's pick
BBC
15 October 2014
Hepatitis C treatment

As Hepatitis Pill Harvoni Joins Sovaldi, States Erect Medicaid Hurdles

Editor's pick
Forbes
10 October 2014
New & experimental hepatitis C treatment

U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C

Editor's pick
Gilead press release
10 October 2014
Hepatitis C treatment

Thousands of Hep C patients in Alexandria wait in long lines to receive Sovaldi

Editor's pick
Egypt Independent
10 October 2014
Hepatitis C treatment

Sovaldi ‘unaffordable’ says NHS documents

Editor's pick
Pharmafile
8 October 2014
Hepatitis C treatment

CVS: One In 12 Hepatitis C Patients Not Adhering To $1,000/Day Pill

Editor's pick
Forbes
7 October 2014
Hepatitis C treatment

Most Spanish patients coinfected with HIV/HCV called difficult to cure

Editor's pick
Healio
7 October 2014
Hepatitis C treatment

New Hepatitis C Treatment Too Pricey For All Patients

Editor's pick
KJZZ Radio
7 October 2014
Hepatitis C treatment

France uses tax to put pressure on hepatitis C drug prices

Editor's pick
Reuters
1 October 2014
New & experimental hepatitis C treatment

After Patient's Death, Study Shows HCV Drug Cardiotoxic in 14 of 34 Treated Patients

Editor's pick
Medscape (requires registration)
29 September 2014
New & experimental hepatitis C treatment

European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults

Editor's pick
Gilead press release
29 September 2014
Hepatitis C treatment

Why Gilead’s Recent Deal with Generic Producers for its Hepatitis C Drugs (Sofosbuvir and Ledipasvir) is a Sham

Editor's pick
ITPC
25 September 2014
Hepatitis C treatment

NICE consults on draft guidance on the drug simeprevir (Olysio) for treating hepatitis C

Editor's pick
NICE
25 September 2014
Hepatitis C treatment

As Gilead Mulls Price of Next Hepatitis C Drug, Top Activist Refutes "Bogus" Math

Editor's pick
TheBody.com
24 September 2014
Hepatitis C treatment

Hepatitis C: Sit in of European patients to request access to new medicines, on occasion of the informal meeting of European Health Ministers in Milan

Editor's pick
EATG
22 September 2014
Hepatitis C treatment

The new $84,000 hepatitis C treatment is losing momentum, for now

Editor's pick
Washington Post
22 September 2014
Hepatitis C treatment

Thousands register for new hepatitis C drug in Egypt sold at 99 percent discount

Editor's pick
Egyptian Streets
19 September 2014
Hepatitis C treatment

Community Leaders, HIV Doctors Oppose Hepatitis C Treatment Barriers

Editor's pick
HIVandhepatitis.com
17 September 2014
Access to healthcare

Gilead’s Proposed Hepatitis C Medicines License: How Badly Will it Miss the Target?

Editor's pick
Infojustice
17 September 2014
Hepatitis C treatment

Access to sofosbuvir in middle-income countries

Editor's pick
I-MAK
17 September 2014
Hepatitis C treatment

Gilead Deal to Sell Sovaldi in Poor Countries Meets Criticism

Editor's pick
Pharmalot
16 September 2014